1Gawronska B, Leuschner C, Enright F M, et al. Effects of a lytic peptide conjugated to beta HCG on ovarian cancer: studies in vitro and in vivo. Gynecol Oncol,2002, 85(1):45～52
2Lundin M, Nordling S, Carpelan-Holmstrom M, et al. A comparison of serum and tissue hCG beta as prognostic markers in colorectal cancer. Anticancer Res,2000, 20(6D): 4949～4951
3Marcillac I, Cottu P, Theodore C, et al. Free hCG-beta subunit as tumour marker in urothelial cancer. Lancet,1993, 341(8856):1354～1355
4Okamoto T, Niu R, Matsuo K, et al. Human chorionic gonadotropin beta-core fragment is directly produced by cancer cells. Life Sci,2001, 68(8): 861～872
5Mungan T, Kuscu E, Ugur M, et al. Screening of persistent trophoblastic disease with various serum markers. Eur J Gynaecol Oncol,1998, 19(5): 495～497
6Gregory J J, Finlay J L. Alpha-fetoprotein and beta-human chorionic gonadotropin: their clinical significance as tumour markers. Drugs,1999, 57(4): 463～467
7Hoshi S, Suzuki K, Ishidoya S, et al. Significance of simultaneous determination of serum human chorionic gonadotropin (hCG) and hCG-beta in testicular tumor patients.Int J Urol,2000, 7(6):218～223
8Crawford R A, Iles R K, Carter P G, et al. The prognostic significance of beta human chorionic gonadotrophin and its metabolites in women with cervical carcinoma. J Clin Pathol,1998, 51(9): 685～688
9Triozzi P L, Stevens V C. Human chorionic gonadotropin as a target for cancer vaccines. Oncol Rep,1999, 6(1): 7～17
10Triozzi P L, Stevens V C, Aldrich W, et al. Effects of a beta-human chorionic gonadotropin subunit immunogen administered in aqueous solution with a novel nonionic block copolymer adjuvant in patients with advanced cancer. Clin Cancer Res,1997, 3(12Pt1):2355～2362
1Cole LA. Biological functions of hCG and hCG-related molecules[J]. Reprod Biol Endocrino, 2010, 18: 102.
2Yu N,Xu W,Jiang Z, et al. Inhibition of tumor growth in vitro andin vivo by a monoclonal antibody against human chorionicgonado-tropin beta[ J]. Immunol Lett, 2007, 114(2) : 94 -102.
3Yang J, Zhang Y, Wang H, et al. Vaccination with the repeat p-hCGC-terminal peptide carried by heat shock protein-65 (HSP65) forinducing antitumor effects[J]. Tumour Biol, 2012, 33(5) : 1777 -1784.
4Moulton HM, Yoshihara PH, Mason DH, et al. Active specificimmunotherapy with a beta-human chorionic gonadotropin peptidevaccine in patients with metastatic colorectal cancer: antibodyresponse is associated with improved survival [ J ] . Clin Cancer Res,2002,8(7) : 2044 - 2051.
5Butler SA, Staite EM, lies RK. Reduction of bladder cancer cellgrowth in response to hCG beta CTP37 vaccinatedmouse serum [ J ].Oncol Res, 2003, 14(2): 93 -100.
6Yi H, Rong Y, Yankai Z, et al. Improved efficacy of DNA vaccina-tion against breast cancer by boosting with the repeat beta-hCG C-terminal peptide carried by mycobacte heat-shock protein HSP65[J]. Vaccine, 2006,24(14) : 2575 -2584.
7Guan QD, Wang Y, Chu YW, et al. The distinct effects of threetandem repeats of C3 d in the immune responses against tumor-associ-ated antigen hCG by DNA immunization[ J]. Cancer Immunol Im-munother, 2007,56(6) : 875 - 884.
8Li D, Wen X,Ghali L, et al. hCG爲expression by cervical squamouscarcinoma-ira vivo histological association withtumor invasion andapoptosis[ J]. Histopathology, 2008, 53(2) : 147 -155.
9lies RK. Ectopic hCGbeta expression by epithelial cancer: malignantbehaviour,metastasis and inhibition of tumor cell apoptosis[ J]. MolCell Endocrinol, 2007 , 260 : 264 -270.
10Vartiainen J, Lassus H, Lehtovirta P, et al. Combination of serum hCGbeta and p53 tissue egression defines distinct subgroups of serous ovari-an carcinoma[J]. Int J Cancer, 2008, 122(9) : 2125 -2129.
